Abstract:INTRODUCTION Non–small cell lung cancer (NSCLC) has been one of the most lethal malignancies around the world. Adenocarcinoma of the lung is the most common type of lung cancer and accounts for 30% to 35% of primary lung tumors (1). Currently, systemic chemotherapy is still an important treatment option for patients with advanced lung adenocarcinoma (2). Docetaxel (DTX) has become an integral part of several commonly used chemotherapy regimens in NSCLC (3). However, the development of intrinsic or acquired resistance to DTX remains the greatest obstacle to the successful treatment of patients with lung adenocarcinoma. Thus, elucidating the mechanisms by which DTX resistance arises in lung adenocarcinoma remains a critical issue for overcoming and predicting DTX resistance in NSCLC. Recently, a wealth of novel insights into molecular targets and mechanisms of cancer chemosensitivity and resistance have yielded much progress in genomic and proteomic studies (4). DTX (Taxotere) is a novel microtubule-stabilizing agent that has been synthesized from a precursor extracted from a renewable natural source, the needles of the European yew, Taxus baccata (5). This agent can enhance microtubule assembly and inhibit the depolymerization of tubulin. In the clinical setting, DTX has been used for adjuvant therapy after resection of localized NSCLC and in combination with radiation for locally advanced NSCLC and treatment of patients with advanced NSCLC (6,7). However, the therapeutic results in some patients with advanced NSCLC have been unsatisfying, as in cases of intrinsic or acquired chemoresistance. The dysregulation of oncogenes such as Bcl-2 family members or tumor suppressors such as PUMA (p53 upregulated modulator of apoptosis) has been found to be associated with DTX resistance of tumor cells (8–10). However, the molecular mechanisms of DTX resistance are very complicated and require further elucidation. Previously, we successfully established a DTX-resistant lung adenocarcinoma cell line (SPC-A1/DTX) from a DTXnonresistant lung adenocarcinoma cell Identification of ING4 (Inhibitor of Growth 4) as a Modulator of Docetaxel Sensitivity in Human Lung Adenocarcinoma

Nimotuzumab increases chemosensitivity of human lung adenocarcinoma cell lines to docetaxel.

Nimotuzumab Abrogates Acquired Radioresistance of KYSE-150R Esophageal Cancer Cells by Inhibiting EGFR Signaling and Cellular DNA Repair

Nimotuzumab increased chemosensitivity of human lung adenocarcinoma docetaxel-resistant cell line

The Effects of Nimotuzumab Alone and in Combination with Chemotherapy on Pulmonary Adenocarcinoma

Nimotuzumab Signiifcantly Enhances Chemosensitivity of PC9 Human Lung Adenocarcinoma Cells to Paclitaxel in vitro

A Phase I Study of Nimotuzumab Plus Docetaxel in Chemotherapy- Refractory/resistant Patients with Advanced Non-Small-cell Lung Cancer

High-dose Nimotuzumab Improves the Survival Rate of Esophageal Cancer Patients Who Underwent Radiotherapy.

Inhibition of ZEB1 Reverses EMT and Chemoresistance in Docetaxel-Resistant Human Lung Adenocarcinoma Cell Line.

Establishment and Characterization of a Docetaxel-Resistant Human Prostate Cancer Cell Line.

The Antitumor Effects Of Cik Cells Combined With Docetaxel Against Drug-Resistant Lung Adenocarcinoma Cell Line Spc-A1/Dtx In Vitro And In Vivo

Nimotuzumab Combined With Irradiation Enhances the Inhibition to the HPV16 E6-Promoted Growth of Cervical Squamous Cell Carcinoma

Nimotuzumab Plus Concurrent Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma: the Randomized, Phase 3 CC3 Study.

Nimotuzumab and irinotecan synergistically induce ROS‐mediated apoptosis by endoplasmic reticulum stress and mitochondrial‐mediated pathway in cervical cancer

MLN4924 Neddylation Inhibitor Promotes Cell Death in Paclitaxel-Resistant Human Lung Adenocarcinoma Cells.

Safety and Efficacy of Nimotuzumab in Combination with Radiotherapy for Patients with Squamous Cell Carcinoma of the Esophagus

The anti-tumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX in vitro and in vivo

MiR-140-3p Improves Sensitivity to Docetaxel by Suppressing PD-L1/ABCG2/MVP Expression in Lung Adenocarcinoma

Identification of ING 4 ( Inhibitor of Growth 4 ) as a Modulator of Docetaxel Sensitivity in Human Lung Adenocarcinoma

Nimotuzumab Combined with Radiotherapy on Esophageal Cancer: Preliminary Study of a Phase II Clinical Trial.

The Antitumor Effects of CIK Cells Combined with Docetaxel Against Drug-Resistant Lung Adenocarcinoma Cell Line SPC-A1/DTX in Vitro and in Vivo.

NSC 74859-mediated inhibition of STAT3 enhances the anti-proliferative activity of cetuximab in hepatocellular carcinoma.